Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 68Ga or 18F for Prostate Cancer Imaging?

Literature DB >> 28408526

⁶⁸Ga or ¹⁸F for Prostate Cancer Imaging?

Claudia Kesch¹, Clemens Kratochwil², Walter Mier², Klaus Kopka³, Frederik L Giesel⁴.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2017 PMID： 28408526 DOI： 10.2967/jnumed.117.190157

Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057

Keyword Cloud
Cited

× No keyword cloud information.

33 in total

1. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging.

Authors: Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Jeffrey P Leal; Takahiro Higuchi; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal: J Nucl Med Date: 2018-09-06 Impact factor: 10.057

2. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.

Authors: Johan Hygum Dam; Birgitte Brinkmann Olsen; Christina Baun; Poul Flemming Høilund-Carlsen; Helge Thisgaard
Journal: Mol Imaging Biol Date: 2017-12 Impact factor: 3.488

Review 3. The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.

Authors: Yishen Wang; Joao R Galante; Athar Haroon; Simon Wan; Asim Afaq; Heather Payne; Jamshed Bomanji; Sola Adeleke; Veeru Kasivisvanathan
Journal: Nat Rev Urol Date: 2022-07-04 Impact factor: 16.430

4. Synthesis, preclinical evaluation, and first-in-human study of Al¹⁸F-PSMA-Q for prostate cancer imaging.

Authors: Yitian Wu; Xiaojun Zhang; Haoxi Zhou; Baixuan Xu; Jiahe Tian; Shuwei Sun; Jinming Zhang
Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-09 Impact factor: 10.057

5. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted ¹⁸F-DCFPyL in peripheral ganglia.

Authors: Rudolf A Werner; Sara Sheikhbahaei; Krystyna M Jones; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Mohamad E Allaf; Kenneth J Pienta; Constantin Lapa; Andreas K Buck; Takahiro Higuchi; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal: Ann Nucl Med Date: 2017-08-22 Impact factor: 2.668

6. Diagnostic performance of ¹⁸F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.

Authors: Kambiz Rahbar; Ali Afshar-Oromieh; Robert Seifert; Stefan Wagner; Michael Schäfers; Martin Bögemann; Matthias Weckesser
Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-20 Impact factor: 9.236

7. Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT.

Authors: Jochen Hammes; Melanie Hohberg; Philipp Täger; Markus Wild; Boris Zlatopolskiy; Philipp Krapf; Bernd Neumaier; Klaus Schomäcker; Carsten Kobe; Matthias Schmidt; Markus Dietlein; Alexander Drzezga
Journal: PLoS One Date: 2018-12-20 Impact factor: 3.240

8. Automated GMP compliant production of [¹⁸F]AlF-NOTA-octreotide.

Authors: Térence Tshibangu; Christopher Cawthorne; Kim Serdons; Elin Pauwels; Willy Gsell; Guy Bormans; Christophe M Deroose; Frederik Cleeren
Journal: EJNMMI Radiopharm Chem Date: 2020-01-29

9. Synthesis and Initial Characterization of a Reversible, Selective ¹⁸F-Labeled Radiotracer for Human Butyrylcholinesterase.

Authors: Christian Gentzsch; Xinyu Chen; Philipp Spatz; Urban Košak; Damijan Knez; Naoko Nose; Stanislav Gobec; Takahiro Higuchi; Michael Decker
Journal: Mol Imaging Biol Date: 2021-03-03 Impact factor: 3.488

10. Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov.

Authors: Claus Zippel; Sarah C Ronski; Sabine Bohnet-Joschko; Frederik L Giesel; Klaus Kopka
Journal: Pharmaceuticals (Basel) Date: 2020-01-13